Clinical trials: Hormone Replacement
Nicotine Dependence
Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine
Unfortunately, the investigators still need to assess and identify novel ways to help people quit smoking. Differences between people in terms of how fast they metabolize nicotine influences response to transdermal nicotine…
- Trial name
- HDP (NCT00956943)
- Testing
- Nicoderm CQ transdermal nicotine
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Smoking Cessation
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
Nicotine replacement therapy (NRT) is a well-tolerated and efficacious smoking cessation treatment, and yet many smokers fail to quit using NRT.
- Trial name
- ConNic3 (NCT00894166)
- Testing
- Nicotine Patches, Nicotine patches, then bupropion & nicotine patches (Pre-Quit), Nicotine patches, then varenicline (Pre-Quit)
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Duke University
Fabry Disease
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
This is an open label switch over study to assess the safety and efficacy of PRX-102 (pegunigalsidase alfa). Patients treated with agalsidase alfa for at least 2 years and on a stable dose (>80% labelled dose/kg) for at least 6…
- Trial name
- NCT03018730
- Testing
- PRX-102 (pegunigalsidase alfa)
- Where
- 9 sites in Australia, Canada and 5 more
- Volunteers
- 22 people
- Sponsor
- Protalix
Nicotine Dependence
Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers
The purpose of this study is to better characterize differences in mood, attention, brain activation patterns underlying the beneficial effects of pharmacological treatments previously demonstrated to be help individuals…
- Trial name
- NCT01048944
- Testing
- Bupropion SR, Nicotine Patch
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Southern Illinois University Carbondale
Glaucoma, Ocular Hypertension
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior brimonidine 0.2%/timolol 0.5% fixed combination (COMBIGAN®) therapy in patients with open-angle glaucoma or ocular…
- Conditions
- Glaucoma, Ocular Hypertension, Open-angle Glaucoma
- Trial name
- NCT01415401
- Testing
- Brinzolamide 1% / timolol 0.5% maleate fixed combination
- Volunteers
- 57 people
- Sponsor
- Alcon Research
Anemia
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
This study will evaluate whether anemia prevention with NeoRecormon has an additional impact on reducing cardiovascular risk over conventional anemia treatment in patients mostly with stage IV chronic kidney disease and renal…
- Trial name
- NCT00321919
- Testing
- epoetin beta [NeoRecormon]
- Where
- 93 sites in Austria, Belgium and 20 more
- Volunteers
- 605 people
- Sponsor
- Hoffmann-La Roche
Hypogonadism, Cardiovascular Diseases
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
This is a double-blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with pre-existing cardiovascular disease (CVD) or increased risk for CVD.
- Trial name
- TRAVERSE (NCT03518034)
- Testing
- AndroGel®
- Where
- 384 sites in United States, Puerto Rico
- Volunteers
- 5,246 people
- Sponsor
- AbbVie
Smoking Cessation
Smoking Cessation in Hispanic Construction Workers
Construction workers have the highest rate of smoking among all occupations, and are frequently exposed to a wide range of workplace hazards (e.g. toxins), which interact with smoking to increase their health risks.
- Trial name
- NCT02873377
- Testing
- Nicorette Gum, Nicoderm CQ, Smoking Quitline Referral
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Miami
Primary Immunodeficiency Diseases (PID)
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16…
- Trial name
- NCT05755035
- Testing
- TAK-881, HYQVIA
- Where
- 32 sites in United States, Czechia and 6 more
- Volunteers
- 65 people
- Sponsor
- Takeda
Secondhand Smoke
Parent eReferral to Tobacco Quitline
Secondhand smoke (SHS) exposure is a significant public health problem in that it both harms children and is widely prevalent, affecting more than 40% of US children.
- Trial name
- NCT02997735
- Testing
- Quitline Delivered Treatment
- Where
- United States
- Volunteers
- 484 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Acute Kidney Injury
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).
- Trial name
- NCT01400893
- Testing
- SCD
- Where
- 26 sites in United States
- Volunteers
- 134 people
- Sponsor
- SeaStar Medical
Anemia
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
This study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on dialysis.
- Trial name
- NCT00048048
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Gaucher Disease, Type 1
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular…
- Trial name
- NCT00553631
- Testing
- velaglucerase alfa, imiglucerase
- Where
- 11 sites in United States, Argentina and 7 more
- Volunteers
- 34 people
- Sponsor
- Shire
Stimulant Use & Co-occuring Opioid Use Disorders
Stimulant Oxytocin Study
This study will investigate the effects of intranasal administration of oxytocin, a social neuropeptide, on reducing stimulant use, enhancing therapeutic engagement, and susceptibility to stress-induced relapse in Veterans with…
- Trial name
- SOS (NCT03016598)
- Testing
- Intranasal oxytocin
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- VA Office of Research and Development
Tobacco Use Cessation
Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts
The overall goal of this research project is to examine the feasibility, acceptability, and preliminary efficacy of nicotine replacement therapy preloading (NRT-P) in HIV-positive smokers, who are struggling with cigarette…
- Trial name
- NCT04994444
- Testing
- Nicoderm CQ 21Mg/24Hr Transdermal System
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Brown University
Breast Cancer
Radiologic Evaluation and Breast Density (READ)
The purpose of this study is to determine whether cessation of hormone replacement therapy for one or two months before a screening mammogram will improve its performance by decreasing breast density.
- Trial name
- NCT00117663
- Testing
- temporary discontinuation of hormone therapy for 1 month, temporary discontinuation of hormone therapy for 2 months
- Where
- United States
- Volunteers
- 1,704 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Growth Hormone Deficiency, Traumatic Brain Injury
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Fifteen to twenty percent of adults who suffer a traumatic brain injury (TBI) that requires hospitalization and rehabilitation have been found to have growth hormone (GH) deficiency by GH stimulation testing.
- Trial name
- NCT00957671
- Testing
- Recombinant human growth hormone
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Tobacco Smoking
Trial Comparing Different Methods of Support With Stopping Smoking (PORTSSS/Stop Together Trial)
This study shall determine whether or not proactive telephone support for smoking cessation delivered to quitline callers is more effective than standard 'reactive' provision and whether or not the offer of a voucher for a cost…
- Trial name
- PORTSSS (NCT00775944)
- Testing
- Proactive telephone support, Reactive (standard) telephone support, Offer of voucher for cost-free Nicotine Replacement Therapy
- Where
- United Kingdom
- Volunteers
- 2,591 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Fabry Disease
A Study of Fabrazyme in Pediatric Patients With Fabry Disease
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme.
- Trial name
- NCT00074958
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
Tobacco Dependence
Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking
This study is to see if a new nicotine replacement therapy safely helps people to quit smoking if it is used the way it would be if it were sold at the pharmacy and used at home.
- Trial name
- NCT01296698
- Testing
- Nicotine
- Where
- 19 sites in United States
- Volunteers
- 257 people
- Sponsor
- McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.